肺癌分子靶向治療進(jìn)展(已修改)
2025-06-07 18:13 本頁(yè)面
【正文】 腫瘤新生血管形成與腫瘤發(fā)展 腫瘤 抑制劑 細(xì)胞毒藥物 /針對(duì)腫瘤靶向藥物 血管抑制劑 作用機(jī)制 抑制腫瘤細(xì)胞生長(zhǎng)和阻斷血管生成蛋白合成 (例如 bFGF，VEGF， TGFa) 抑制內(nèi)皮細(xì)胞對(duì)血管生成蛋白VEGF起作用 bFGF VEGF TGFa 內(nèi)皮細(xì)胞 Sandler AB, et al. Proc ASCO 2022。23:127 (Abs. 2022) “ 抗血管生成療法 ” 示意圖 細(xì)胞癌變 小腫瘤 腫瘤生長(zhǎng) 分泌生長(zhǎng)因子 誘發(fā)新生血管 新生血管向腫瘤供養(yǎng) 癌細(xì)胞通過(guò)血管擴(kuò)散 腫瘤休眠 血 管 阻斷新生血管 血 管 血 管 新生血管生成與腫瘤生長(zhǎng)、轉(zhuǎn)移的關(guān)系 Adapted from Poon RT, et al. J Clin Oncol 2022。19:1207–25 新生血管生成在腫瘤發(fā)展過(guò)程的不同階段所扮演的角色 惡變前期 惡性腫瘤 腫瘤生長(zhǎng) 血管侵襲 微轉(zhuǎn)移處于 休眠狀態(tài) 明顯的轉(zhuǎn)移 (腫瘤無(wú)血管 ) (血管新生開(kāi)始 ) (腫瘤形成血管 ) (腫瘤細(xì)胞進(jìn)入血管內(nèi) ) (遠(yuǎn)道種植 ) (再次形成新生血管 ) 30,663 papers published on angiogenesis from 1967 April 2022 1,846 as of April 1, 2022 0 500 1000 1500 2022 2500 3000 3500 4000 4500 5000 1967 1969 1971 1973 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2022 2022 2022 2022 Years Number of papers 4456 in 2022 3 in 1971 38 in 1980 198 in 1990 Angiostatin Endostatin Avastin Macugen The VEGF family are critical tumorsecreted angiogenic factors ? The vascular endothelial growth factor (VEGF) family are critical tumor secreted signaling molecules that stimulate angiogenesis and lymphangiogenesis ? There are five members of the VEGF family (VEGFA, VEGFB, VEGFC, VEGFD, VEGFE) VEGFB VEGFA VEGFE VEGFC VEGFD VEGFs bind to VEGF receptors on endothelial cells ? VEGF family members bind to surface receptors on endothelial cells ? There are three VEGF receptors: VEGFR1, VEGFR2, and VEGFR3 ? VEGFR1 and
數(shù)學(xué)相關(guān)推薦
鄂ICP備17016276號(hào)-1